# Richard J. Ulevitch

> Richard J. Ulevitch is a Series B investor at 5AM Ventures backing Biotechnology. See 11 investments, check sizes, portfolio and contact details. Updated Sep…

- Type: Angel Investor
- Fund: [5AM Ventures](https://shizune.co/investors/profile/5am-ventures)
- Total investments: 11
- Last investment: Jun 2015
- Lead investor: 9%
- Last updated: Sep 2026
- LinkedIn: https://www.linkedin.com/in/richard-ulevitch-46ab99b

Richard J. Ulevitch is a Series B investor at 5AM Ventures focused on Biotechnology and Life Science. Richard J. Ulevitch, PhD joined 5AM Ventures in February 2008 as a Venture Partner.Previously he was Chairman of the 5AM Scientific Advisory Board while serving as Professor and Chairman of the Department of Immunology at The Scripps Research Institute, La Jolla, California. He remains as Professor and Chairman Emeritus at The Scripps ResearchInstitute.For nearly three decades, Dr. Ulevitch has performed research to understand the role of the immune system in human disease. He serves as a scientific advisor to Aravis Ventures, a European life science venture capital fund and previously served as an advisor to the Lombard Odier Immunology Fund, where he evaluated numerous biotechnology companies over a fifteen year span.Dr. Ulevitch serves on the Scientific Advisory Board of Cleave, Igenica, Pulmatrix and RuiYi (previously Anaphore) and formerly was a member of Scientific Advisory Boards at Envoy (acquired by Takeda) and Ikaria

## Contacts

5 contacts available for Richard J. Ulevitch: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/richard-j-ulevitch?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 27% |
| Life Science | 2 | 18% |
| Therapeutics | 2 | 18% |
| Medical | 1 | 9% |
| Pharmaceutical | 1 | 9% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 27% |
| Series A | 2 | 18% |
| Series C | 1 | 9% |
| Post-IPO Equity | 1 | 9% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Pulmatrix | Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaledanti-fungal for patients with ABPA, and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by achieving optimal local drug concentrations and reducing systemic side effects to improve patient outcomes. | $10M | Post-IPO Equity | Jun 16, 2015 | http://www.pulmatrix.com |
| Bird Rock Bio | Bird Rock Bio is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. RYI-008 is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicatedin inflammation and cancer. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company’s technologies, including the iCAP (intramembranous Conformation Antigen Presenting) system. Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators. | $15M | Series B | Mar 27, 2014 | http://www.birdrockbio.com/ |
| Igenica | Igenica Biotherapeutics is focused on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. They are the only biotherapeutic company that fully powers the ADC development spectrum from a clinically relevant approach to target and functional antibody discovery to ADC creation, acceleratingdevelopment and the delivery of effective therapies to patients.Founded in 2009, Igenica is led by a proven team of leaders that have demonstrated success in antibody drug discovery, clinical development and commercialization. Their leadership team has played a seminal role in six out of the 36 currently approved antibody therapeutic products.Based in Burlingame, Calif., they are well-funded by a premier team of life science investors including The Column Group, OrbiMed, 5AM Ventures and Third Rock Ventures. | $14M | Series C | Jan 28, 2014 | http://www.igenica.com |
| Igenica | Igenica Biotherapeutics is focused on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. They are the only biotherapeutic company that fully powers the ADC development spectrum from a clinically relevant approach to target and functional antibody discovery to ADC creation, acceleratingdevelopment and the delivery of effective therapies to patients.Founded in 2009, Igenica is led by a proven team of leaders that have demonstrated success in antibody drug discovery, clinical development and commercialization. Their leadership team has played a seminal role in six out of the 36 currently approved antibody therapeutic products.Based in Burlingame, Calif., they are well-funded by a premier team of life science investors including The Column Group, OrbiMed, 5AM Ventures and Third Rock Ventures. | $33M | Series C | Jun 12, 2012 | http://www.igenica.com |
| Pulmatrix | Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaledanti-fungal for patients with ABPA, and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by achieving optimal local drug concentrations and reducing systemic side effects to improve patient outcomes. | $14M | Series B | Aug 15, 2011 | http://www.pulmatrix.com |
| Igenica | Igenica Biotherapeutics is focused on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. They are the only biotherapeutic company that fully powers the ADC development spectrum from a clinically relevant approach to target and functional antibody discovery to ADC creation, acceleratingdevelopment and the delivery of effective therapies to patients.Founded in 2009, Igenica is led by a proven team of leaders that have demonstrated success in antibody drug discovery, clinical development and commercialization. Their leadership team has played a seminal role in six out of the 36 currently approved antibody therapeutic products.Based in Burlingame, Calif., they are well-funded by a premier team of life science investors including The Column Group, OrbiMed, 5AM Ventures and Third Rock Ventures. | $24M | Series B | Jun 14, 2010 | http://www.igenica.com |
| Pulmatrix | Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaledanti-fungal for patients with ABPA, and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by achieving optimal local drug concentrations and reducing systemic side effects to improve patient outcomes. | $30.2M | Series B | Nov 02, 2009 | http://www.pulmatrix.com |
| Bird Rock Bio | Bird Rock Bio is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. RYI-008 is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicatedin inflammation and cancer. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company’s technologies, including the iCAP (intramembranous Conformation Antigen Presenting) system. Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators. | $13M | Series A | May 14, 2009 | http://www.birdrockbio.com/ |
| Pulmatrix | Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaledanti-fungal for patients with ABPA, and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by achieving optimal local drug concentrations and reducing systemic side effects to improve patient outcomes. | $3.5M | Series A | Mar 11, 2009 | http://www.pulmatrix.com |
| Bird Rock Bio | Bird Rock Bio is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. RYI-008 is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicatedin inflammation and cancer. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company’s technologies, including the iCAP (intramembranous Conformation Antigen Presenting) system. Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators. | $25M | Series A | Jan 07, 2009 | http://www.birdrockbio.com/ |

10 of 11 investments shown.

## Co-investors
- [Polaris Partners](https://shizune.co/investors/profile/polaris-partners) — VC Fund, 4 deals together
- [SR One](https://shizune.co/investors/profile/sr-one) — VC Fund, 3 deals together
- [The Column Group](https://shizune.co/investors/profile/the-column-group) — VC Fund, 3 deals together
- [Versant Ventures](https://shizune.co/investors/profile/versant-ventures) — VC Fund, 3 deals together
- [Aravis Ventures](https://shizune.co/investors/profile/aravis-ventures) — VC Fund, 2 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 2 deals together

## About 5AM Ventures

VC Fund · Menlo Park, United States

5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.

5 contacts available at 5AM Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| John Diekman | Founder & Managing Partner | https://shizune.co/investors/profile/john-d-diekman |
| Kush Parmar | Managing Partner | https://shizune.co/investors/profile/kush-parmar |
| Richard J. Ulevitch | Venture Partner | https://shizune.co/investors/profile/richard-j-ulevitch |
| Scott Rocklage | Founding Partner | https://shizune.co/investors/profile/scott-m-rocklage |
| Andrew Schwab | Managing Partner | https://shizune.co/investors/profile/andrew-schwab |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Richard J. Ulevitch invest in?

Richard J. Ulevitch invests primarily in Biotechnology, Life Science and Therapeutics startups, most often at Series B and Series A stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Richard J. Ulevitch?

Public channels for Richard J. Ulevitch include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Richard J. Ulevitch last invest?

The most recent investment recorded for Richard J. Ulevitch closed in Jun 2015. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co